Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4+T Cell Changes During Peg-IFN-α vs Nucleoside Analogues in Chronic Hepatitis B
NCT03209011Phase 4Unknown
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in hepatitis B (HBV) (2 arms). Primary endpoint: Changes of CD4+ T Cells Frequency and Function at 24 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03209011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209011.